ReviewMacromolecular bioscience2025
Engineering Efferocytosis for Bone Regeneration.
Review in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cel-LDH dual-functional nanotherapy simultaneously promotes microglial efferocytosis and alleviates neuronal apoptosis for spinal cord injury recovery.Journal of nanobiotechnology · 2026Article
- Impaired Macrophage Efferocytosis: Shared Mechanisms and Therapeutic Implications in Immune-Mediated Inflammatory Diseases.Journal of inflammation research · 2026Review
- Engineering Efferocytosis for Bone Regeneration.Macromolecular bioscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bone is an incredibly robust tissue thanks to its high blood supply, rapid cell turnover, and continuous remodeling. A significant body of research investigates strategies to improve osteogenesis, angiogenesis, and immunomodulation for bone regeneration, facilitated by numerous various therapeutic approaches (e.g. pharmacologics, biomaterials, stem cell therapy, and more). However, a critically understudied but recently emerging area of research lies in the inflammatory cascade and the cleanup of apoptotic cells during repair, aging, and disease. Termed "efferocytosis," this natural and efficient cleaning up of cells at the end of their lifespan is a crucial step in resolving injury, controlling disease, maintaining homeostasis, and tissue repair. Currently, the primary mechanism(s) driving efferocytosis in most tissue but especially bone, is unknown. Despite this knowledge gap, mounting evidence suggests that impaired efferocytosis plays a significant role in many chronic illnesses and impairs tissue regeneration. Biomaterials-based interventions are well-positioned to interrogate mechanisms of efferocytosis due to their ability to provide local support and guide cellular activity not only in combination with but also without additional pharmaceutical aid. This review will highlight the current understanding of efferocytosis in bone and discuss cutting-edge biomaterials-based strategies to engineer efferocytosis for improved outcomes in bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.